S

Scholar Rock Holding Corporation (SRRK)

NMS – Real vaqt narxi. Valyuta: USD

49.19

+0.84 (1.74%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

S

Scholar Rock Holding Corporation (SRRK)

NMS – Real vaqt narxi. Valyuta: USD

49.19

+0.84 (1.74%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

09.05.2026

Scholar Rock Q1 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company's investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.

07.05.2026

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

07.05.2026

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments. “With the FDA's acc.

29.04.2026

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas, NV, on May 12, 2026 at 8:00 a.m. PT / 11:.

17.04.2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

16.04.2026

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please reg.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments. “With the FDA's acc.

17.04.2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

31.03.2026

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of children and adults with SMA to the U.S.

13.03.2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

Search stocks

Scholar Rock Holding Corporation (SRRK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Scholar Rock Holding Corporation (SRRK)

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Scholar Rock Q1 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Videolar

No Data

Press-relizlar

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)